Secukinumab (AIN457) for the treatment of psoriasis
A Lopez-Ferrer, E Vilarrasa, L Puig - Expert Review of Clinical …, 2015 - Taylor & Francis
Psoriasis is a chronic inflammatory disease with a multifactorial origin that appears in
patients with genetic predisposition and is induced by environmental factors, and …
patients with genetic predisposition and is induced by environmental factors, and …
Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
D Thaci, J Humeniuk, Y Frambach… - British Journal of …, 2015 - academic.oup.com
Background Secukinumab, an anti‐interleukin‐17A monoclonal antibody, has demonstrated
rapid and sustained efficacy in phase 3 psoriasis trials. Objectives To examine whether …
rapid and sustained efficacy in phase 3 psoriasis trials. Objectives To examine whether …
Real‐life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2‐year period
M Megna, E Camela, E Cinelli… - Clinical and …, 2020 - academic.oup.com
Background The prevalence of psoriasis is increasing among older people. Elderly patients
with psoriasis represent a challenge for dermatologists owing to multiple comorbidities …
with psoriasis represent a challenge for dermatologists owing to multiple comorbidities …
Treatment of psoriasis with secukinumab in challenging patient scenarios: a review of the available evidence
JJ Wu, JF Merola, SR Feldman, A Menter… - Dermatology and …, 2020 - Springer
Psoriasis (PsO) is a common, systemic, chronic, inflammatory disease characterized by key
clinical symptoms, including itching, pain, and scaling. PsO is associated with a high …
clinical symptoms, including itching, pain, and scaling. PsO is associated with a high …
Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5‐year results from the phase 3 FUTURE 1 study
PJ Mease, A Kavanaugh, A Reimold… - ACR open …, 2020 - Wiley Online Library
Objective To report the 5‐year efficacy and safety of secukinumab in the treatment of
patients with psoriatic arthritis (PsA) in the FUTURE 1 study (NCT 01392326). Methods …
patients with psoriatic arthritis (PsA) in the FUTURE 1 study (NCT 01392326). Methods …
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) …
PJ Mease, R Landewé, P Rahman, H Tahir… - RMD open, 2021 - rmdopen.bmj.com
Objective Secukinumab provided sustained efficacy, low radiographic progression and
consistent safety over 52 weeks in patients with psoriatic arthritis (PsA) in the FUTURE 5 …
consistent safety over 52 weeks in patients with psoriatic arthritis (PsA) in the FUTURE 5 …
Use of secukinumab in a cohort of erythrodermic psoriatic patients: a pilot study
G Damiani, A Pacifico, F Russo, PDM Pigatto… - Journal of Clinical …, 2019 - mdpi.com
Erythrodermic psoriasis (EP) is a dermatological emergency and its treatment with
secukinumab is still controversial. Furthermore, no data exist regarding the prognostic value …
secukinumab is still controversial. Furthermore, no data exist regarding the prognostic value …
Efficacy and safety of secukinumab in a psoriatic patient affected by comorbid metabolic disorders
G Babino, E Fulgione, CM Giorgio… - Dermatologic …, 2019 - Wiley Online Library
Psoriasis is a common, chronic, immune‐mediated disease occurring more frequently in
association with comorbid metabolic disorders. The management of patients with multiple …
association with comorbid metabolic disorders. The management of patients with multiple …
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority …
U Mrowietz, CL Leonardi, G Girolomoni, D Toth… - Journal of the American …, 2015 - Elsevier
Background Secukinumab has demonstrated high, sustained efficacy in psoriasis to 52
weeks on a fixed-interval regimen. Objective We sought to compare a retreatment-as …
weeks on a fixed-interval regimen. Objective We sought to compare a retreatment-as …
[HTML][HTML] Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab
TS Chiu, TF Tsai - Dermatologica Sinica, 2019 - journals.lww.com
Methods: We reviewed the treatment efficacy of all patients with moderate-to-severe
psoriasis who used secukinumab as monotherapy and did not reach Psoriasis Area Severity …
psoriasis who used secukinumab as monotherapy and did not reach Psoriasis Area Severity …